14-1-4-3　ⓔ文献

  1. Ho KM, Power BM: Benefits and risks of furosemide in acute kidney injury. Anaesthesia, 2010; 65: 283–293.

  2. Ho KM, Sheridan DJ: Meta–analysis of frusemide to prevent or treat acute renal failure. BMJ, 2006; 333: 420.

  3. AKI (急性腎障害) 診療ガイドライン作成委員会：AKI (急性腎障害) 診療ガイドライン2016，東京医学社，2016．

  4. Nigwekar SU, Navaneethan SD, et al: Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev, 2009: CD006028.

  5. 日本腎臓学会編：エビデンスに基づくCKD診療ガイドライン 2018，東京医学社，2018．

  6. 日本高血圧学会高血圧治療ガイドライン作成委員会編：高血圧診療ガイドライン 2019，ライフサイエンス出版，2019．

  7. Williamson JD, Supiano MA, et al: Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: A randomized clinical trial. JAMA, 2016; 315: 2673-2682.

  8. Kovesdy CP, Alrifai A, et al: Age and Outcomes Associated with BP in Patients with Incident CKD. Clin J Am Soc Nephrol, 2016; 11: 821–831.

  9. 丸山彰一監，厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究班編：エビデンスに基づくネフローゼ症候群診療ガイドライン 2017，東京医学社，2017．

  10. Shiiki H, Saito T, et al: Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int, 2004; 65: 1400–1407.

  11. Yamaguchi M, Ando M, et al: Patient age and the prognosis of idiopathic membranous nephropathy. PLoS One, 2014; 9: e110376.

  12. Saito T, Iwano M, et al: Significance of combined cyclosporine–prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid–resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol, 2014; 18: 784–794.

  13. 丸山彰一監，厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究班編：エビデンスに基づくIgA腎症診療ガイドライン 2017，東京医学社，2017．

  14. 丸山彰一監，厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究班編：エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン 2017，東京医学社，2017．

  15. Appel GB, Contreras G, et al: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol, 2009; 20: 1103–1112.

  16. 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究 (自己免疫班)，日本リウマチ学会編：全身性エリテマトーデス診療ガイドライン 2019，南山堂，2019．

  17. Iijima K, Sako M, et al: Rituximab for childhood–onset, complicated, frequently relapsing nephrotic syndrome or steroid–dependent nephrotic syndrome: a multicentre, double–blind, randomised, placebo–controlled trial. Lancet, 2014; 384: 1273–1281.

  18. Jones RB, Tervaert JW, et al: Rituximab versus cyclophosphamide in ANCA–associated renal vasculitis. N Engl J Med, 2010; 363: 211–220.

  19. Stone JH, Merkel PA, et al: Rituximab versus cyclophosphamide for ANCA–associated vasculitis. N Engl J Med, 2010; 363: 221–232.

  20. Zhang F, Bae SC, et al: A pivotal phase III, randomised, placebo–controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis, 2018; 77: 355–363.

  21. Singhal R, Brimble KS: Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res, 2006; 118: 397–407.

  22. 丸山彰一監，厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 難治性腎疾患に関する調査研究班編：エビデンスに基づく多発性囊胞腎 (PKD) 診療ガイドライン 2017，東京医学社，2017．

  23. Torres VE, Chapman AB, et al: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med, 2012; 367: 2407–2418.

  24. Wanner C, Inzucchi SE, et al: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med, 2016; 375: 323–334.

  25. Neal B, Perkovic V, et al: Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS–R): A randomized, placebo–controlled trial. Diabetes Obes Metab, 2017; 19: 387–393.

  26. Jardine MJ, Mahaffey KW, et al: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol, 2017; 46: 462–472.

  27. Akizawa T, Asano Y, et al: Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis, 2009; 54: 459–467.

  28. Hayashino Y, Fukuhara S, et al: Cost-effectiveness of administering oral adsorbent AST–120 to patients with diabetes and advance–stage chronic kidney disease. Diabetes Res Clin Pract, 2010; 90: 154–159.

  29. Tsubakihara Y, Gejyo F, et al: High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non–dialysis chronic kidney disease patients. Ther Apher Dial, 2012; 16: 529–540.

  30. Kovesdy CP, Kuchmak O, et al: Outcomes associated with phosphorus binders in men with non–dialysis–dependent CKD. Am J Kidney Dis, 2010; 56: 842–851.